RxDoctor Payments Data

George Dillon, MD

Vascular Neurology · Clinton Township, MINPI 1598023665

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.6% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations.

$3,786in general payments, 2019–2025

Across 211 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$391
  • Novartis$288
  • Lilly USA, LLC$278
  • Genentech USA, Inc.$233
  • Alnylam Pharmaceuticals Inc.$222
  • Pfizer$198
  • plus $2K from 40 others
$17,661in research payments, 2019–2025

Across 2 payments — averaging $8830.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$18K

What the payments were for

  • Speaking & faculty fees$261%
  • Food & beverage$3,65897%
  • Education$1023%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,786 in reported general payments places this provider in the 65th percentile of 29 vascular neurology providers in Michigan.

See all vascular neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$259,747
Medicare patients
705
Services billed
2,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate13$74,103
Emgality PenGalcanezumab-Gnlm29$22,186
Rivastigmine12$2,857
Memantine Hcl94$2,467
Carbidopa-LevodopaCarbidopa/Levodopa60$1,280
Oxcarbazepine14$1,150
RivastigmineRivastigmine Tartrate13$904
Levetiracetam31$585
Primidone19$482
Gabapentin45$428
Pregabalin27$413
Quetiapine Fumarate31$352
Donepezil Hcl36$246
Carbidopa-Levodopa ErCarbidopa/Levodopa11$211
Topiramate26$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$146$74,10313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 29 vascular neurology providers in Michigan.

Other vascular neurology in Clinton Township

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →